Comparison
Exenatide vs. Sermorelin
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Growth
CAS no.
141758-74-9
86168-78-7
Molecular weight
4186.6 g/mol
3358 g/mol
Half-life
2.4 h
0.2 h
Sequence
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSYADAIFTNSYRKVLGQLSARKLLQDIMSRMechanism of action
Exenatide
Exenatide is a 39-amino-acid peptide with about 53% sequence homology to human GLP-1. A glycine substitution at position 2 prevents dipeptidyl-peptidase-IV cleavage and extends the half-life from native GLP-1 (minutes) to about 2.4 hours. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon and delays gastric emptying.
Sermorelin
Synthetic analogue of the first 29 amino acids of human growth-hormone-releasing hormone (GHRH). Stimulates pulsatile endogenous growth-hormone secretion from the pituitary via the GHRH receptor. Very short plasma half-life — pharmacodynamic effect lasts several hours nevertheless.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
5
5
of which in humans
4
3
Effects recorded
3
3
Open conflicts
1
1
Documented adverse events
2
3